Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the 340b Program topic
No spam. Unsubscribe anytime.
Michigan hospitals defend 340B discounts as reporters question drug markups
Summary
Michigan Hospital Association officials told the House Insurance Committee that the federal 340B drug-pricing program helps hospitals extend community programs and that hospital charges, payments and reimbursement are distinct concepts that the public-report analysis conflated.
The Michigan Health & Hospital Association told the Michigan House Insurance Committee on May 30 that the federal 340B drug-pricing program helps hospitals lower acquisition costs for outpatient medicines and fund community health programs, amid recent press reports that compared billed charges across hospitals.
Elizabeth Cutter, senior director for government and political affairs at the Michigan Health & Hospital Association, said hospitals use 340B savings to support community needs tailored to each locale, from $0 co-pay cancer care to sustaining rural labor-and-delivery units. "One of the hallmarks of the program...is it is not specific about how you use those savings, which means each of our individual members ... can reflect on their community needs," Cutter said.
Why it matters: The committee and the association debated whether 340B savings translate into lower premiums or lower out‑of‑pocket costs for insured patients. Association officials said the program lowers hospitals' acquisition cost for certain outpatient drugs, improving hospital margins in a system where Medicare and Medicaid payments often do not cover full costs.
Cutter and Laura Pell, executive vice president for government relations and public policy at the MHA, responded directly to a Detroit Free Press analysis cited by Chair Harris that found large markups for three specialty drugs across Michigan hospitals. "We have not been able to duplicate those findings," Cutter said, and she described instances in which the dataset appeared to count inpatient-billing conventions against outpatient drugs.
The association explained that hospitals record a single charge for a given service but accept different payments depending on the payer: commercial insurers negotiate payment levels, while Medicare and Medicaid are set by statute or regulation. "We must charge everybody the same thing," Pell said, noting a Medicare regulatory requirement that hospitals apply consistent charges even though final payments differ by payer.
Association officials also described legal and operational constraints on how discounts are applied. Pell noted that hospitals cannot duplicate discounts (for example, a Medicaid rebate and a 340B discount on the same product) and that compliance with federal program rules constrains how savings may be passed on.
On whether 340B reduces insurance premiums, Cutter said the program affects hospitals' margins — which can help offset shortfalls from government payers — but she did not claim a direct, mechanical reduction in premiums. "You might be able to purchase that drug at a discount, but you're going to get reimbursed what you've negotiated with your payer," Cutter said.
Procedural notes: The committee approved minutes from its May 21 meeting by motion of Representative Leitner and later adjourned after a motion by Representative Fitzgerald.
Ending: Committee members requested follow-up materials, including detailed community-impact and charity-care reports the association said it would provide.
